Antitumor and Immunopotentiating Activity of Polysaccharide PST001 Isolated from the Seed Kernel of Tamarindus indica: An In Vivo Study in Mice

Table 4

Tumor and hematological characteristics in mice injected with EAC on day 1 followed by drug administration for 14 days and dissected on 15th day (Group 2).

Concentration	EAC control	PST 200 mg/kg	5-FU 20 mg/kg	PST + 5-FU
Tumor volume(mL)	10.2±0.72	4.8±0.26 ***	3.9±0.13 ***	3.4±0.1 ***
Body weight (g)	31.82±1.5	29.14±2.3 *	27.47±1.7 **	26.23±2.5 **
PCV(mL)	3.1±0.26	1.4±0.26 ***	0.9±0.21 ***	0.7±0.13 ***
Mean survival time (Days)	19 ± 0.98	28 ± 0.99***	33 ± 1***	38 ± 1.7***
% Increase in life span (ILS)	—	47.3±0.84 ***	73.68±0.93 ***	100 ± 1***
Tumor cell count (10^6cells/mL)	175 ± 2	58 ± 1***	39 ± 1.3***	32 ± 1***
Percentage of viable cells	93 ± 1	75 ± 2***	70 ± 0.5***	68 ± 1***
Percentage of nonviable cells	7 ± 1	25 ± 0.57**	30 ± 2**	32 ± 1***
Hb (G%) (12.2–16.2) gm/dL	11 ± 0.5	12±1^ns	12.2±0.8^ns	12.4±0.6^ns
RBC (Million/cmm) (7–12.5) × 10^6/mm^3	3.6 ± 1	4.2±1.2^ns	4.3±0.5^ns	4.4±1^ns
TC (c/mm) (5100–11600)	17500 ± 600	10100 ± 550***	9300 ± 300***	8200 ± 150***
Platelets (/cmm) (160000–410000)	203000 ± 150	250000 ± 235***	301000 ± 195***	350000 ± 210***

Data were expressed as mean ± SD (𝑛=6) on day 15 of the experiment. Statistically significant differences are at *𝑃<0.05, **𝑃<0.01, ***𝑃<0.001; ns is the non-significant, as compared with control group.